Drug Trial Radar · NCT01344447
Gadobutrol Enhanced MRA of the Supra-aortic Vessels
Last checked: Nov 19, 2026Latest source record: Jan 4, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
479
Actual
Start
May 12, 2011
Primary completion
May 28, 2014
Study completion May 28, 2014
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Apr 29, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Subjects referred for a routine CTA (computed tomography angiography) or MRA (magnetic resonance angiography) will be invited to participate in the study and subjects will be involved in the study for between 2 and 12 days. Two to three visits to the study doctor will be required. This study will compare the diagnostic results of Gadobutrol enhanced MRA images with MRA images taken without contrast agent using images from a CTA as the standard of reference, which may have been performed up to 60 days prior to enrolment. If a CTA has not been performed in this prior time period, a CTA is required for the study. MRA and CTA images will be collected for an independent review (blinded read).
Conditions
- Carotid Stenosis
Interventions
Gadobutrol (Gadovist, BAY86-4875)Drug
A single bolus injection of approx. 0.1mmol/kg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Assessable Vascular Segments Using Gadobutrol-Enhanced MRA and Unenhanced MRATime frame: Images were taken pre-injection and post-injection
- Sensitivity for Detection of Clinically Significant Disease Using Gadobutrol-Enhanced MRA and Unenhanced MRATime frame: Images were taken pre-injection and post-injection
- Specificity for Exclusion of Clinically Significant Disease Using Gadobutrol-Enhanced MRA and Unenhanced MRATime frame: Images were taken pre-injection and post-injection
- Minimum Gadobutrol Performance for Sensitivity: Sensitivity > 50%Time frame: Images were taken pre-injection and post-injection
- Minimum Gadobutrol Performance for Specificity: Specificity > 50%Time frame: Images were taken pre-injection and post-injection
Locations
56 sites in 14 countries. Site status is shown where the registry gives one.
Site not named
Tucson, Arizona
Site not named
Jacksonville, Florida
Site not named
Savannah, Georgia
Site not named
Louisville, Kentucky
Site not named
Baltimore, Maryland
Site not named
Boston, Massachusetts
Site not named
Ann Arbor, Michigan
Site not named
Jackson, Mississippi
Site not named
Rochester, New York
Site not named
The Bronx, New York
Site not named
Philadelphia, Pennsylvania
Site not named
Providence, Rhode Island
Site not named
Memphis, Tennessee
Site not named
Seattle, Washington
Site not named
Madison, Wisconsin
Site not named
Adrogué, Buenos Aires, Argentina
Site not named
Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina
Site not named
Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina
Site not named
New Lambton Heights, New South Wales, Australia
Site not named
Clayton, Victoria, Australia
Site not named
Parkville, Victoria, Australia
Site not named
Vienna, Austria
Site not named
Innsbruck, Tyrol, Austria
Site not named
Shanghai, China
Site not named
Shanghai, China
Site not named
Brno, Czechia
Site not named
Brest, France
Site not named
Bron, France
Site not named
Marseille, France
Site not named
Paris, France
Site not named
Paris, France
Site not named
Karlsruhe, Baden-Wurttemberg, Germany
Site not named
Augsburg, Bavaria, Germany
Site not named
Erlangen, Bavaria, Germany
Site not named
Münster, North Rhine-Westphalia, Germany
Site not named
Jena, Thuringia, Germany
Site not named
Aosta, Aosta Valley, Italy
Site not named
Ferrara, Emilia-Romagna, Italy
Site not named
Rome, Lazio, Italy
Site not named
Catania, Sicily, Italy
Showing 40 of 56 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.